BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: A combination of imatinib and a BH3 mimetic may prove to be beneficial for resistant CML cells bearing mutations in BIM, but would seem ineffective on patients with lower levels of BAX, as BAK does not seem to compensate for the lack of BAX.